ArticleAmerican journal of hematology2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Article in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.Blood cancer journal · 2024Trial
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.BMC cancer · 2024Article
- Autologous stem cell transplantation in AL amyloidosis: Muddy waters.Blood reviews · 2024Review
- Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.Clinical and experimental medicine · 2024Article
- Article
- A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots.Frontiers in medicine · 2024Article
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Bad players in AL amyloidosis in the current era of treatment.Expert review of hematology · 2023Article
- Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.Journal of cancer research and clinical oncology · 2022Article
- Biomarkers in AL Amyloidosis.International journal of molecular sciences · 2021Review
- Comprehensive Review of AL amyloidosis: some practical recommendations.Blood cancer journal · 2021Review
- Characterization and prognostic implication of delayed complete response in AL amyloidosis.European journal of haematology · 2021Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Future Perspectives.Hematology/oncology clinics of North America · 2020Review
- Review
- CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.International journal of molecular sciences · 2020Review
- Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.Frontiers in pharmacology · 2020Review
- Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 2 countries.
Funding
Abstract
We evaluated bone marrow minimal residual disease (MRD) negativity in 44 patients with light chain (AL) amyloidosis using next generation flow cytometry (sensitivity ≥1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.